Hyperion DeFi (HYPD) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Talphera (TLPH) has outperformed Hyperion DeFi (HYPD) over the past year, losing 18.2% versus a loss of 62.9%. Over five years, TLPH leads with a -94.7% price change compared with -99.2% for HYPD. Talphera is the larger company by market cap ($56.1 million vs $51.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYPD | TLPH |
|---|---|---|
| Share price | $3.37 | $1.08 |
| Market cap | $51.16M | $56.06M |
| 1-day change | -6.27% | +2.86% |
| YTD return | -5.48% | -5.26% |
| 1-year return | -62.86% | -18.18% |
| 5-year return | -99.21% | -94.71% |
| EPS (TTM) | $-6.06 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.50 | $1.57 |
| 52-week low | $2.34 | $0.69 |
| Distance from 52-week high | -64.58% | -31.21% |
| Analyst consensus | none | none |
| Avg. price target upside | +192.12% | +189.81% |
| Average volume | 445.34K | 238.38K |
| Shares outstanding | 15.20M | 51.91M |
| Employees | 9 | 12 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLPH has outperformed HYPD by 44.7 percentage points over the past year.
About Hyperion DeFi
HYPD stock →Hyperion DeFi, Inc., a DeFi company, engages in building on Hyperliquid. It operates through two segments: Ophthalmic Technology and Digital Assets.
Healthcare · Biotechnology · 9 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Healthcare · Drug Manufacturers - Specialty & Generic · 12 employees
HYPD vs TLPH FAQ
Which is bigger, Hyperion DeFi or Talphera?
Talphera (TLPH) is larger, with a market capitalization of $56.06M compared with $51.16M for Hyperion DeFi (HYPD).
Which stock has performed better over the past year, HYPD or TLPH?
TLPH returned -18.18% over the past 12 months, compared with -62.86% for HYPD (price return, excluding dividends). Past performance does not predict future results.
Are Hyperion DeFi and Talphera in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Hyperion DeFi and Drug Manufacturers - Specialty & Generic for Talphera.